Atossa Therapeutics' CEO, Dr. Steven Quay, will participate in a panel at Harvard's ARDD 2026 meeting to discuss translating aging research into new drug therapies and regulatory pathways. The panel will cover clinical trial design, therapeutic development, and regulatory considerations, highlighting advances in aging biology and their impact on drug development. This event underscores Atossa's focus on expanding treatments for rare diseases using strong biological evidence. The meeting gathers industry and academic leaders to explore innovations in aging-related drug discovery and clinical development.
Atossa Therapeutics CEO Dr. Steven Quay's participation in ARDD 2026 offers context for readers interested in health sector trends. For readers following health stocks, here is Pluang's market snapshot as of Sep 24, 2026 18:22 WIB: of 100 priced Health-sector US stocks, 37 rose and 59 fell. Notable movers include INCY at USD 128.65 (+3.22%), INO at USD 1.21 (-3.20%, with 83% sell order activity), and NUWE at USD 0.82 (-3.17%, with 56% sell order activity).
Bernstein upgraded Dollar General to "Outperform" due to its strategic initiatives targeting budget shoppers and expanding seasonal product offerings, especially affordable toys. The company is also growing its DG Media Network, which generates signi...
TD SYNNEX reported quarterly earnings per share of $5.68, surpassing analyst estimates of $4.70 by 22.41%, and revenue of $21.56 billion, beating estimates by 14.81%. This strong performance reflects a 37.7% revenue increase year-over-year, driving t...
Cintas reported a 10.9% revenue increase to $3.01 billion in Q1 fiscal 2027 and exceeded EPS expectations with $1.39 per share. Following this strong performance, investment firm Robert W. Baird raised its price target for Cintas to $222, implying a ...
Darden Restaurants reported Q1 2027 earnings per share of $2.05, meeting analyst expectations but down from $2.19 last year due to higher expenses. Total revenue was $3.20 billion, just below the $3.21 billion estimate. Despite this, the company saw ...
Jefferies Financial Group is expected to report a third-quarter revenue of $2.21 billion, marking an 8.1% increase year-over-year, signaling strong sales growth. However, earnings per share (EPS) are forecasted to decline slightly by 1% to around $1....
